Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SYHA1815 |
Synonyms | |
Therapy Description |
SYHA1815 is a selective RET inhibitor with activity against RET V804 mutants, potentially leading to inhibition of cell proliferation and tumor growth (PMID: 34518294). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SYHA1815 | SYHA-1815|SYHA 1815 | RET Inhibitor 53 | SYHA1815 is a selective RET inhibitor with activity against RET V804 mutants, potentially leading to inhibition of cell proliferation and tumor growth (PMID: 34518294). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET C634W | medullary thyroid carcinoma | sensitive | SYHA1815 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, SYHA1815 treatment inhibited RET signaling and proliferation of a medullary thyroid cancer cell line harboring RET C634W in culture, and induced tumor regression in a cell line xenograft model (PMID: 34518294). | 34518294 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|